SynRx Therapeutics
- Biotech or pharma, therapeutic R&D
SynRx is a clinical-stage biotechnology company advancing the next-generation therapeutics through synthetic lethality. We have successfully achieved dual IND filings in both China and the U.S. for the two lead programs:
- SYN818, a highly selective DNA polymerase theta (POLQ) helicase inhibitor, currently advancing toward Phase 1b in combination with Olaparib for the treatment of breast and ovarian cancers.
- SYN608, a best-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor, entering Phase 1 as a monotherapy for breast, gynecological, and gastrointestinal malignancies.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}